Vericel (VCEL) 10-K 13 Mar 14 2013 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
	Dec. 31, 2013	Feb. 28, 2014	Jun. 28, 2013
Document and Entity Information	'	'	'
Entity Registrant Name	'AASTROM BIOSCIENCES INC	'	'
Entity Central Index Key	'0000887359	'	'
Document Type	'10-K	'	'
Document Period End Date	31-Dec-13	'	'
Amendment Flag	'false	'	'
Current Fiscal Year End Date	'--12-31	'	'
Entity Well-known Seasoned Issuer	'No	'	'
Entity Voluntary Filers	'No	'	'
Entity Current Reporting Status	'Yes	'	'
Entity Filer Category	'Smaller Reporting Company	'	'
Entity Public Float	'	'	$18,237,155
Entity Common Stock, Shares Outstanding	'	6,158,389	'
Document Fiscal Year Focus	'2013	'	'
Document Fiscal Period Focus	'FY	'	'

CONSOLIDATED_BALANCE_SHEETS

CONSOLIDATED BALANCE SHEETS (USD $)	Dec. 31, 2013	Dec. 31, 2012
CURRENT ASSETS:	'	'
Cash	$8,059,000	$13,638,000
Other current assets	417,000	352,000
Total current assets	8,476,000	13,990,000
PROPERTY AND EQUIPMENT, NET	739,000	1,188,000
Total assets	9,215,000	15,178,000
CURRENT LIABILITIES:	'	'
Accounts payable and accrued expenses	2,676,000	3,247,000
Accrued employee benefits	620,000	383,000
Current portion of long-term debt	6,000	34,000
Warrant liabilities	2,019,000	1,995,000
Total current liabilities	5,321,000	5,659,000
LONG-TERM DEBT	'	6,000
Total liabilities	5,321,000	5,665,000
COMMITMENTS AND CONTINGENCIES (Notes 8 and 9)	'	'
Total convertible preferred stock	'	41,613,000
Shareholders' equity (deficit):	'	'
Common Stock, no par value; shares authorized -7,500 and 15,000, respectively; shares issued and outstanding -2,189 and 4,723, respectively	253,270,000	243,215,000
Deficit accumulated during the development stage	-287,765,000	-275,315,000
Total shareholders' equity (deficit)	3,894,000	-32,100,000
Total liabilities, convertible preferred stock and shareholders' equity (deficit)	9,215,000	15,178,000
Series B-1 non-voting convertible preferred stock	'	'
CURRENT LIABILITIES:	'	'
Total convertible preferred stock	'	3,923,000
Series B-2 voting convertible preferred stock	'	'
CURRENT LIABILITIES:	'	'
Total convertible preferred stock	'	37,690,000
Series B-2 voting convertible preferred stock	'	'
Shareholders' equity (deficit):	'	'
Total convertible preferred stock	($38,389,000)	'

CONSOLIDATED_BALANCE_SHEETS_Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Par value of common stock (in dollars per share)	'	'
Common Stock, shares authorized	15,000,000	7,500,000
Common Stock, shares issued	4,723,000	2,189,000
Common Stock, shares outstanding	4,723,000	2,189,000
Series B-1 non-voting convertible preferred stock	'	'
Par value of convertible preferred stock (in dollars per share)	'	'
Convertible preferred stock, shares authorized	'	39,000
Convertible preferred stock, shares reserved	'	39,000
Convertible preferred stock, shares issued	'	0
Convertible preferred stock, shares outstanding	'	0
Series B-2 voting convertible preferred stock	'	'
Par value of convertible preferred stock (in dollars per share)	'	'
Convertible preferred stock, shares authorized	'	39,000
Convertible preferred stock, shares reserved	'	39,000
Convertible preferred stock, shares issued	'	12,000
Convertible preferred stock, shares outstanding	'	12,000
Series B-2 voting convertible preferred stock	'	'
Par value of convertible preferred stock (in dollars per share)	'	'
Convertible preferred stock, shares authorized	39,000	'
Convertible preferred stock, shares reserved	39,000	'
Convertible preferred stock, shares issued	12,000	'
Convertible preferred stock, shares outstanding	12,000	'

CONSOLIDATED_STATEMENTS_OF_OPE

CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)	12 Months Ended			297 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2013
REVENUES:	'	'	'	'
Product sales and rentals	$19	$21	$18	$1,917
Research and development agreements	'	'	'	2,105
Grants	'	'	'	9,901
Total revenues	19	21	18	13,923
COSTS AND EXPENSES:	'	'	'	'
Cost of product sales and rentals	4	6	4	3,051
Research and development	15,104	26,025	21,330	231,834
Selling, general and administrative	5,875	7,750	7,724	98,473
Total costs and expenses	20,983	33,781	29,058	333,358
LOSS FROM OPERATIONS	-20,964	-33,760	-29,040	-319,435
OTHER INCOME (EXPENSE):	'	'	'	'
Decrease in fair value of warrants	5,337	4,248	9,329	21,874
Other income	'	'	'	1,249
Interest income	16	50	53	10,838
Interest expense	-11	-12	-10	-502
Total other income (expense)	5,342	4,286	9,372	33,459
NET LOSS	($15,622)	($29,474)	($19,668)	($285,976)
NET LOSS PER SHARE ATTRIBUTABLE TO COMMON SHAREHOLDERS (Basic and Diluted) (see note 5) (in dollars per share)	($6.95)	($16.25)	($10.18)	'
Weighted average number of common shares outstanding (Basic and Diluted)	3,016	2,060	1,931	'

CONSOLIDATED_STATEMENTS_OF_SHA

CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (DEFICIT) (USD $)

Total

Preferred Stock

Common Stock

Deficit Accumulated During the Development Stage

1998 Series I Convertible Preferred Stock

1998 Series I Convertible Preferred Stock

1998 Series I Convertible Preferred Stock

1999 Series III Convertible Preferred Stock

1999 Series III Convertible Preferred Stock

1999 Series III Convertible Preferred Stock

5.5% Convertible Preferred Stock

5.5% Convertible Preferred Stock

Series A Preferred Stock

Series A Preferred Stock

Series E Preferred Stock

Series E Preferred Stock

Series B-2 voting convertible preferred stock

Preferred Stock

Common Stock

Preferred Stock

Common Stock

Preferred Stock

Preferred Stock

Preferred Stock

Common Stock

BALANCE at Mar. 24, 1989

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Increase (Decrease) in Shareholders' Equity

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net loss

($221,212,000)

'

'

($221,212,000)

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of common stock for cash, services and license rights

2,336,000

'

2,336,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of common stock for cash, services and license rights (in shares)

'

'

7,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of preferred stock

'

'

'

'

4,689,000

4,540,000

149,000

2,810,000

2,720,000

90,000

9,930,000

9,930,000

34,218,000

34,218,000

3,500,000

-3,500,000

'

Issuance of preferred stock (in shares)

'

'

'

'

'

5,000

1,000

'

3,000

1,000

'

2,200,000

'

9,452,000

206,000

'

'

Exercise of stock options and stock purchase warrants, and issuance of stock under Employee Stock Purchase Plan

8,791,000

'

8,791,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise of stock options and stock purchase warrants, and issuance of stock under Employee Stock Purchase Plan (in shares)

'

'

72,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of Stock Purchase Rights for cash in September 1995 and March 1996

3,500,000

'

3,500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Principal payment received under shareholder note Receivable

31,000

'

31,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Initial public offering of common stock at $1,120 per share, net of issuance costs of $2,865

19,885,000

'

19,885,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Initial public offering of common stock at $1,120 per share, net of issuance costs of $2,865 (in shares)

'

'

20,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Conversion of preferred stock

'

-55,374,000

55,374,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Conversion of preferred stock (in shares)

'

-11,866,000

136,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Compensation expense related to stock options, restricted stock, and warrants granted

10,132,000

'

10,132,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of common stock, net of issuance costs of $980, $147, $13,424 during the period ended December 31, 2013, December 31, 2012 and December 31, 2010 respectively

126,942,000

'

126,942,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of common stock, net of issuance costs of $980, $147, $13,424 during the period ended December 31, 2013, December 31, 2012 and December 31, 2010 respectively (in shares)

'

'

1,685,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of restricted stock, net of cancellations (in shares)

'

'

3,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of stock under Direct Stock Purchase Plan

943,000

'

943,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of stock under Direct Stock Purchase Plan (in shares)

'

'

5,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Dividends and yields on preferred stock

'

466,000

502,000

-968,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Dividends and yields on preferred stock (in shares)

'

'

1,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Repurchase and retirement of common shares outstanding

-73,000

'

-73,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

BALANCE at Dec. 31, 2010

2,922,000

'

225,102,000

-222,180,000

'

'

'

'

'

'

'

'

'

'

'

'

'

BALANCE (in shares) at Dec. 31, 2010

'

'

1,931,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Increase (Decrease) in Shareholders' Equity

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net loss

-19,668,000

'

'

-19,668,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise of stock options and stock purchase warrants, and issuance of stock under Employee Stock Purchase Plan

32,000

'

32,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise of stock options and stock purchase warrants, and issuance of stock under Employee Stock Purchase Plan (in shares)

'

'

1,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Compensation expense related to stock options, restricted stock, and warrants granted

3,743,000

'

3,743,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

BALANCE at Dec. 31, 2011

-12,971,000

'

228,877,000

-241,848,000

'

'

'

'

'

'

'

'

'

'

'

'

'

BALANCE (in shares) at Dec. 31, 2011

'

'

1,932,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Increase (Decrease) in Shareholders' Equity

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net loss

-33,467,000

'

'

-33,467,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise of stock options and stock purchase warrants, and issuance of stock under Employee Stock Purchase Plan

214,000

'

214,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise of stock options and stock purchase warrants, and issuance of stock under Employee Stock Purchase Plan (in shares)

'

'

7,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Compensation expense related to stock options, restricted stock, and warrants granted

3,610,000

'

3,610,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of common stock, net of issuance costs of $980, $147, $13,424 during the period ended December 31, 2013, December 31, 2012 and December 31, 2010 respectively

10,514,000

'

10,514,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of common stock, net of issuance costs of $980, $147, $13,424 during the period ended December 31, 2013, December 31, 2012 and December 31, 2010 respectively (in shares)

'

'

250,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

BALANCE at Dec. 31, 2012

-32,100,000

'

243,215,000

-275,315,000

'

'

'

'

'

'

'

'

'

'

'

'

'

BALANCE (in shares) at Dec. 31, 2012

'

'

2,189,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Increase (Decrease) in Shareholders' Equity

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net loss

-15,622,000

'

'

-15,622,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Reclassification of Series B-2 Preferred Stock

'

'

'

3,224,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Compensation expense related to stock options, restricted stock, and warrants granted

926,000

'

926,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Reclassification of Series B-2 Preferred Stock

41,613,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

38,389,000

Reclassification of Series B-2 Preferred Stock (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

12,000

Reverse stock split common stock in lieu of fractional shares

'

'

52,000

-52,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Reverse stock split common stock in lieu of fractional shares (in shares)

'

'

14,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise of stock purchase warrants

1,983,000

'

1,983,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise of stock purchase warrants (in shares)

'

'

367,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of common stock, net of issuance costs of $980, $147, $13,424 during the period ended December 31, 2013, December 31, 2012 and December 31, 2010 respectively

7,094,000

'

7,094,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of common stock, net of issuance costs of $980, $147, $13,424 during the period ended December 31, 2013, December 31, 2012 and December 31, 2010 respectively (in shares)

'

'

2,153,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

BALANCE at Dec. 31, 2013

$3,894,000

$38,389,000

$253,270,000

($287,765,000)

'

'

'

'

'

'

'

'

'

'

'

'

'

BALANCE (in shares) at Dec. 31, 2013

'

12,000

4,723,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

CONSOLIDATED_STATEMENTS_OF_SHA1

CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (DEFICIT) (Parenthetical) (USD $)	12 Months Ended		261 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2010
Common Stock	'	'	'
Issuance of stock, issuance cost	$980	$147	$13,424
Initial public offering of common stock, par value (in dollars per share)	'	'	$1,120
Initial public offering of common stock, issuance costs	'	'	2,865
1998 Series I Convertible Preferred Stock | Preferred Stock	'	'	'
Issuance of stock, issuance cost	'	'	460
Convertible Preferred Stock, par value (in dollars per share)	'	'	$1,000
1999 Series III Convertible Preferred Stock | Preferred Stock	'	'	'
Issuance of stock, issuance cost	'	'	280
Convertible Preferred Stock, par value (in dollars per share)	'	'	$1,000
5.5% Convertible Preferred Stock | Preferred Stock	'	'	'
Issuance of stock, issuance cost	'	'	1,070
Convertible Preferred Stock, rate of interest (as a percent)	'	'	5.50%
Convertible Preferred Stock, par value (in dollars per share)	'	'	$5
Series A Preferred Stock | Preferred Stock	'	'	'
Issuance of stock, issuance cost	'	'	$342
Series E Preferred Stock | Preferred Stock	'	'	'
Convertible Preferred Stock, par value (in dollars per share)	'	'	$17

CONSOLIDATED_STATEMENTS_OF_CAS

CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	12 Months Ended			297 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2013
OPERATING ACTIVITIES:	'	'	'	'
Net loss	($15,622,000)	($29,474,000)	($19,668,000)	($285,976,000)
Adjustments to reconcile net loss to net cash used for operating activities:	'	'	'	'
Depreciation and amortization	489,000	649,000	647,000	8,636,000
Loss on property held for resale	'	'	'	110,000
Amortization of discounts and premiums on investments	'	'	'	-1,704,000
Stock compensation expense	926,000	3,610,000	3,743,000	18,421,000
Decrease in fair value of warrant liabilities	-5,337,000	-4,248,000	-9,329,000	-21,874,000
Inventory write downs	'	'	'	2,240,000
Stock issued pursuant to license agreement	'	'	'	3,300,000
Provision for losses on accounts receivable	'	'	'	204,000
Changes in operating assets and liabilities:	'	'	'	'
Inventories	'	'	'	-2,335,000
Other current assets	-65,000	293,000	-194,000	-646,000
Accounts payable and accrued expenses	-571,000	284,000	63,000	2,444,000
Accrued employee benefits	237,000	-659,000	246,000	620,000
Net cash used for operating activities	-19,943,000	-29,545,000	-24,492,000	-276,560,000
INVESTING ACTIVITIES:	'	'	'	'
Organizational costs	'	'	'	-73,000
Purchase of short-term investments	'	'	'	-217,041,000
Maturities of short-term investments	'	'	'	218,745,000
Property and equipment purchases	-40,000	-273,000	-1,031,000	-7,530,000
Proceeds from sale of property held for resale	'	'	'	400,000
Net cash provided used for investing activities	-40,000	-273,000	-1,031,000	-5,499,000
FINANCING ACTIVITIES:	'	'	'	'
Net proceeds from issuance of preferred stock	'	37,620,000	'	89,267,000
Net proceeds from issuance of common stock and warrants	14,438,000	346,000	32,000	199,492,000
Payments received for stock purchase rights	'	'	'	3,500,000
Proceeds from long-term debt	'	'	'	751,000
Payments on long-term debt	-34,000	-40,000	-227,000	-2,874,000
Other, net	'	'	'	-18,000
Net cash provided by (used for) financing activities	14,404,000	37,926,000	-195,000	290,118,000
NET INCREASE (DECREASE) IN CASH	-5,579,000	8,108,000	-25,718,000	8,059,000
CASH AT BEGINNING OF PERIOD	13,638,000	5,530,000	31,248,000	'
CASH AT END OF PERIOD	8,059,000	13,638,000	5,530,000	8,059,000
SUPPLEMENTAL CASH FLOW INFORMATION:	'	'	'	'
Interest paid	11,000	13,000	16,000	515,000
Equipment acquired under capital lease obligations	'	'	52,000	1,295,000
Accretion of convertible preferred stock	1,263,000	3,993,000	'	6,224,000
Warrants exchanged for common stock	'	$10,382,000	'	$10,382,000

Organization_and_Summary_of_Si

Organization and Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2013
Organization and Summary of Significant Accounting Policies	'
Organization and Summary of Significant Accounting Policies	'
	1.     Organization and Summary of Significant Accounting Policies
	Aastrom Biosciences, Inc. was incorporated in March 1989 (Inception), began employee-based operations in 1991, and is in the development stage.  The Company operates its business in one reportable segment — research and product development involving the development of patient-specific cell products for use in regenerative medicine.
	Successful future operations are subject to several technical hurdles and risk factors, including satisfactory product development, timely initiation and completion of clinical trials, regulatory approval and market acceptance of the Company’s products and the Company’s continued ability to obtain future funding.
	The Company is subject to certain risks related to the operation of its business and development of its products and product candidates. As of December 31, 2013 the Company had $8,059,000 of cash.  This is not sufficient to sustain operations for one year.  In light of its financial position, the Company is evaluating strategic financial opportunities in the short-term in order to maintain adequate liquidity through December 31, 2013 and beyond.  The Company could sell common shares through an At Market Sales Agreement (ATM) in order to raise additional capital, though there are certain factors, such as volume of trading in the stock, the stock price and the ability to terminate the agreement with notice, which could limit the amount the Company could raise in a short period of time.  On a longer-term basis, the Company will need to raise additional funds in order to complete product development programs and complete clinical trials needed to market and commercialize its products.  The Company cannot be certain that such funding will be available on favorable terms, if at all.  Some of the factors that will impact the Company’s ability to raise additional capital and its overall success include: the rate and degree of progress for product development, the rate of regulatory approval to proceed with clinical trial programs, the level of success achieved in clinical trials, the requirements for marketing authorization from regulatory bodies in the United States and other countries, the liquidity and market volatility of the Company’s equity securities, regulatory and manufacturing requirements and uncertainties, technological developments by competitors, and other factors.  If the Company cannot raise such funds, the Company will not be able to develop or enhance products, take advantage of future opportunities, or respond to competitive pressures or unanticipated requirements, which would have a material adverse impact on the business, financial condition and results of operations.  As a result of the need to raise additional capital, there is uncertainty regarding the Company’s ability to maintain liquidity sufficient to operate the business effectively over at least the next twelve months, which raises substantial doubt as to the ability to continue as a going concern.  The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.
	Reverse Stock Split — On October 16, 2013, the Company completed a twenty-to-one reverse stock split.  Accordingly, all references to numbers of common stock and per share data in the accompanying financial statements have been adjusted to reflect the reverse stock split on a retroactive basis.
	Principles of Consolidation — The consolidated financial statements include the accounts of Aastrom and its wholly-owned subsidiary, Aastrom Biosciences GmbH, located in Berlin, Germany and Marrow Donation, LLC located in San Diego, California (collectively, the Company).  All inter-company transactions and accounts have been eliminated in consolidation.
	Fair Value Measurements — Fair value is the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants.  As such, fair value is determined based upon assumptions that market participants would use in pricing an asset or liability.  Fair value measurements are rated on a three-tier hierarchy as follows:
	·             Level 1 inputs: Quoted prices (unadjusted) for identical assets or liabilities in active markets;
	·             Level 2 inputs: Inputs, other than quoted prices included in Level 1, that are observable either directly or indirectly; and
	·             Level 3 inputs: Unobservable inputs for which there is little or no market data, which require the reporting entity to develop its own assumptions.
	In many cases, a valuation technique used to measure fair value includes inputs from multiple levels of the fair value hierarchy described above.  The lowest level of significant input determines the placement of the entire fair value measurement in the hierarchy.
	The following table presents the Company’s liabilities that are measured at fair value on a recurring basis at December 31, 2012 and 2013:
		December 31, 2012
		Level 1		Level 2		Level 3
	Warrant liabilities	—		—		$	1,995,000
		December 31, 2013
		Level 1		Level 2			Level 3
	Warrant liabilities	—		$	1,934,000		$	85,000
	A reconciliation of beginning and ending balances for the Company’s fair value measurements using Level 3 inputs is as follows:
	Warrants (in thousands):
		December 31,			December 31,
		2012			2013
	Beginning balance	$	16,625		$	1,995
	Warrants exchanged for common stock	(10,382		)	—
	Warrant issuance	—			5,874
	Warrant exercises	—			(513		)
	Transfers to level 2	—			(2,505		)
	Decrease in fair value	(4,248		)	(4,766		)
	Ending balance	$	1,995		$	85
	The Company utilizes the actual date of an event or change in circumstances to determine if a transfer in or out of a level has occurred.  After the execution of the reverse stock split, the August 2013 warrants no longer contain any anti-dilution provisions that would require Level 3 disclosure.  As a result, they were reclassified to Level 2.  See Note 6 for disclosures related to the fair value of the Company’s warrants.  The Company does not have any other assets or liabilities on the balance sheet as of December 31, 2013 that are measured at fair value.
	Diversity of Credit Risk — The Company has established guidelines relative to diversification and maturities of its investments in an effort to limit risk.  These guidelines are periodically reviewed and modified to take advantage of trends in yields and interest rates.
	Property and Equipment — Property and equipment is recorded at cost and depreciated or amortized using the straight-line method over the estimated useful life of the asset (primarily three to five years) or the underlying lease term for leasehold improvements, whichever is shorter.  When assets are disposed of, the cost and accumulated depreciation are removed from the accounts.  Repairs and maintenance are charged to expense as incurred.
	Revenue Recognition — The Company’s revenue can be generated from grants and research agreements, collaborative agreements, licensing fees and product sales.  Revenue from grants and research agreements is recognized on a cost reimbursement basis consistent with the performance requirements of the related agreement.  Revenue from collaborative agreements is recognized when the scientific or clinical results stipulated in the agreement have been met and there are no ongoing obligations on the Company’s part.  Revenue from product sales is recognized when title to the product transfers and there are no remaining obligations that will affect the customer’s final acceptance of the sale.  Revenue from licensing fees under licensing agreements is recognized when there are no future performance obligations remaining with respect to such revenues.  Payments received before all obligations are fulfilled are classified as deferred revenue.
	Research and Development Costs — Research and development costs are expensed as incurred.  These costs include direct research and development costs such as salaries, clinical trial expenses, consulting fees and other expenses that are specific to the Company’s research and development programs, as well as an allocation of indirect costs such as facility expenses, human resources and information technology expenses.
	Stock-Based Compensation — Calculating stock-based compensation expense requires the input of highly subjective assumptions.  We apply the Black-Scholes option-pricing model to determine the fair value of our stock options.  Inherent in this model are assumptions related to expected stock-price volatility, option life, risk-free interest rate and dividend yield.  We estimate the volatility of our common stock at the date of grant based on historical volatility.  We estimate the expected life of options that vest solely on service using the “simplified method” provided for in the Securities and Exchange Commission Staff Accounting Bulletin No. 110.  The “simplified method” is permitted for estimating the expected term of “plain-vanilla” stock options for which the historical stock option exercise experience is likely not indicative of future exercise patterns.  The risk-free interest rate is based on the U.S. Treasury zero-coupon yield curve on the grant date for a maturity similar to the expected life of the options. The dividend rate is based on our historical rate, which we anticipate to remain at zero.  The assumptions used in calculating the fair value of stock options represent our best estimates; however, these estimates involve inherent uncertainties and the application of management judgment.  As a result, if factors change and different assumptions are used, the stock-based compensation expense could be materially different in the future.  In addition, we are required to estimate the expected forfeiture rate and only recognize expense for those stock options expected to vest over the service period.  We estimate the forfeiture rate considering the historical experience of our stock-based awards.  If the actual forfeiture rate is different from the estimate, we adjust the expense accordingly.
	Income Taxes — Deferred tax assets are recognized for deductible temporary differences and tax credit carryforwards and deferred tax liabilities are recognized for taxable temporary differences.  Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized.
	Net Loss Per Share Attributable to Common Shareholders’— Basic earnings (loss) per share is calculated using the two-class method, which is an earnings allocation formula that determines earnings (loss) per share for the holders of the Company’s common shares and holders of the Series B preferred stock.  The Series B preferred stock shares contain participation rights in undistributed earnings, but do not share in the losses of the Company.  The accumulated but undeclared dividends on the Series B preferred stock of $9,275,000 are treated as a reduction of earnings attributable to common shareholders.
	Use of Estimates — The preparation of financial statements in accordance with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reported period. Actual results could differ from those estimates.
	Financial Instruments — The Company’s financial instruments include receivables for which the current carrying amounts approximate market value based upon their short-term nature.
	Warrants — Warrants that could be cash settled or have anti-dilution price protection provisions are recorded as liabilities at their estimated fair value at the date of issuance, with subsequent changes in estimated fair value recorded in other income (expense) in our statement of operations in each subsequent period.  In general, warrants with anti-dilution provisions are measured using the Monte Carlo valuation model, while the others are measured using the Black-Scholes valuation model.  Both of the methodologies are based, in part, upon inputs for which there is little or no observable market data, requiring the Company to develop its own assumptions.  The assumptions used in calculating the estimated fair value of the warrants represent our best estimates; however, these estimates involve inherent uncertainties and the application of management judgment.  As a result, if factors change and different assumptions are used, the warrant liability and the change in estimated fair value could be materially different.
	Long-Lived Assets — The Company reviews its long-lived assets for impairment whenever an event or change in circumstances indicates that the carrying values of an asset may not be recoverable.  If such an event or change in circumstances occurs and potential impairment is indicated because the carrying values exceed the estimated future undiscounted cash flows of the asset, the Company would measure the impairment loss as the amount by which the carrying value of the asset exceeds its fair value. No significant events or changes in circumstances were identified by the Company that would indicate that the carrying value of an asset was not recoverable for any of the periods presented in the accompanying consolidated financial statements.

Selected_Balance_Sheet_Informa

Selected Balance Sheet Information	12 Months Ended
	Dec. 31, 2013
Selected Balance Sheet Information	'
Selected Balance Sheet Information	'
	2. Selected Balance Sheet Information
	Property and Equipment (in thousands):
		December 31,			December 31,
		2012			2013
	Machinery and equipment	$	2,507		$	2,547
	Furniture and fixtures	706			706
	Computer software	193			193
	Computer equipment	307			307
	Office equipment	55			55
	Leasehold improvements	1,018			1018
		4,786			4,826
	Less accumulated depreciation	(3,598		)	(4,087		)
		$	1,188		$	739
	Accounts Payable and Accrued Expenses (in thousands):
		December 31,			December 31,
		2012			2013
	Accounts payable	$	2,843		$	2,355
	Accrued expenses	404			321
		$	3,247		$	2,676
	Accrued Employee Benefits (in thousands):
		December 31,			December 31,
		2012			2013
	Vacation pay and other	$	383		$	233
	Bonus	—			387
		$	383		$	620

StockBased_Compensation

Stock-Based Compensation	12 Months Ended
	Dec. 31, 2013
Stock-Based Compensation	'
Stock-Based Compensation	'
	3.     Stock-Based Compensation
	Stock Option and Equity Incentive Plans
	The Company has historically had various stock incentive plans and agreements that provide for the issuance of nonqualified and incentive stock options as well as other equity awards.  Such awards may be granted by the Company’s Board of Directors to certain of the Company’s employees, directors and consultants.  Options granted under these plans expire no later than ten years from the date of grant, and other than those granted to non-employee directors, generally become exercisable over a four-year period, under a graded-vesting methodology, following the date of grant.  The Company generally issues new shares upon the exercise of stock options.
	In December 2009, the shareholders approved the 2009 Omnibus Incentive Plan (the 2009 Plan).  The 2009 Plan provides incentives through the grant of stock options, stock appreciation rights, restricted stock awards and restricted stock units.  The exercise price of stock options granted under the 2009 Plan shall not be less than the fair market value of the Company’s common stock on the date of grant.  The 2009 Plan replaced the 1992 Stock Option Plan, the 2001 Stock Option Plan and the Amended and Restated 2004 Equity Incentive Plan (the Prior Plans), and no new awards will be granted under the Prior Plans.  However, the expiration or forfeiture of options previously granted under the Prior Plans will increase the awards available for issuance under the 2009 Plan.
	As of December 31, 2013, there were 369,342 shares available for future grant under the 2009 Plan.
	Service-Based Stock Options
	During the period ended December 31, 2013, the Company granted 75,751 service-based options to purchase common stock.  These were granted with exercise prices equal to the fair value of the Company’s stock at the grant date, generally vest over four years (other than 15,750 non-employee options which generally vest over one year) and have a term of ten years.  The weighted average grant-date fair value of service-based options granted during the year ended December 31, 2011 was $30.80, $24.00 for the year ended December 31, 2012 and $14.07 for the year ended December 31, 2013.
	The net compensation costs recorded for the service-based stock options related to employees, consultants and directors (including the impact of the forfeitures) were $3,743,000 for the year ended December 31, 2011, $3,610,000 for the year ended December 31, 2012 and $926,000 for the year ended December 31, 2013.
	The fair value of each service-based stock option grant for the reported periods is estimated on the date of the grant using the Black-Scholes option-pricing model using the weighted average assumptions noted in the following table.
		Year Ended		Year Ended		Year Ended
		December 31,		December 31,		December 31
	Service-Based Stock Options	2011		2012		2013
	Expected dividend rate	0%		0%		0%
	Expected stock price volatility	72.1% – 78.9%		73.9% – 79.1%		74.0% – 87.9%
	Risk-free interest rate	1.4% – 2.7%		0.9% – 1.5%		0.1% – 2.1%
	Expected life (years)	6.0 – 6.3		5.5 – 6.3		5.0 – 6.3
	The following table summarizes the activity for service-based stock options for the indicated periods:
	Service-Based Stock Options	Options		Weighted Average			Weighted Average	Aggregate
				Exercise Price			Remaining	Intrinsic
							Contractual Term	Value
	Outstanding at December 31, 2010	214,860		$	48.6		8.9	$	3,159,000
	Granted	215,528		$	46.2
	Exercised	(984	)	$	32.8			$	21,000
	Forfeited or expired	(25,420	)	$	46.6
	Outstanding at December 31, 2011	403,984		$	47.6		8.4	$	674,000
	Granted	273,372		$	44.2
	Exercised	(7,208	)	$	29.6			$	52,000
	Cancelled	(52,885	)	$	40.6
	Forfeited or expired	(117,889	)	$	43.6
	Outstanding at December 31, 2012	499,374		$	47.6		7.5	$	—
	Granted	75,751		$	21.32
	Exercised	—		$	—			$	—
	Expired	(164,189	)	$	51.76
	Forfeited	(113,076	)	$	45.38
	Outstanding at December 31, 2013	297,860		$	39.53		7.9	$	—
	Exercisable at December 31, 2013	146,003		$	45.37		7.2	$	—
	As of December 31, 2013, there was approximately $1,621,000, of total unrecognized compensation cost related to non-vested service-based stock options granted under the 2009 Plan and the Prior Plans.  That cost is expected to be recognized over a weighted-average period of 2.7 years.
	The total fair value of stock options vested for the years ended December 31, 2011, 2012 and 2013 was $2,182,000, $2,987,000 and $2,280,000, respectively.

Shareholders_Equity

Shareholders' Equity	12 Months Ended
	Dec. 31, 2013
Shareholders' Equity	'
Shareholders' Equity	'
	4.     Shareholders’ Equity
	On June 16, 2011, the Company entered into an At Market Sales Agreement (as amended to date, the “ATM”) with MLV & CO. LLC (MLV) (formerly McNicoll, Lewis & Vlak LLC), pursuant to which the Company may sell shares of its common stock through MLV, as a sales agent, in registered transactions from its shelf registration statement filed in July 2011, for aggregate proceeds of up to $20,300,000.  Shares of common stock sold under the ATM are to be sold at market prices.  The Company will pay up to 3% of the gross proceeds to MLV as a commission.  From inception of the agreement through December 31, 2013, the Company has raised total gross proceeds of $5,226,000, with gross proceeds of $4,947,000 raised during 2013.  Subsequent to December 31, 2013 through March 6, 2014, the Company has raised gross proceeds of $5,403,000 utilizing the ATM.
	On August 16, 2013, the Company completed the sale of 1,500,000 shares of common stock and warrants to purchase up to an aggregate of 1,500,000 shares of common stock (including 50,000 shares of common stock and warrants sold to the underwriter pursuant to the exercise of its over-allotment option).  Each share of common stock and its associated warrant was sold at a public offering price of $6.00 per share.  The Company received $8,169,000 in net proceeds from the sale of the shares of common stock and warrants (including the partial exercise of the over-allotment option), after underwriting discounts, commissions and other offering expenses.  The total fair market value of the warrants at the date of issuance was $5,874,000.  The sales proceeds were first allocated to the warrants based on the total fair market value and the residual amount of the sales proceeds were allocated to common stock.
	Dividends
	No cash dividends have been declared or paid by the Company since its inception.

Net_Loss_Per_Common_Share

Net Loss Per Common Share	12 Months Ended
	Dec. 31, 2013
Net Loss Per Common Share	'
Net Loss Per Common Share	'
	5.  Net Loss Per Common Share
	The following reflects the net loss attributable to common shareholders and share data used in the basic and diluted earnings per share computations using the two class method:
		Year Ended			Year Ended			Year Ended
		December 31,			December 31,			December 31,
	(Amounts in thousands, except per share amounts)	2011			2012			2013
	Numerator:
	Net loss	$	(19,668	)	$	(29,474	)	$	(15,622	)
	Less: earnings attributable to convertible preferred stock	—			3,993			5,352
	Numerator of basic and diluted EPS	$	(19,668	)	$	(33,467	)	$	(20,974	)
	Denominator:
	Denominator for basic and diluted EPS: weighted-average common shares outstanding	1,931			2,060			3,016
	Net loss per share attributable to common shareholders (basic and diluted)	$	(10.18	)	$	(16.25	)	$	(6.95	)
	Common equivalent shares are not included in the diluted per share calculation where the effect of their inclusion would be anti-dilutive.  The aggregate number of common equivalent shares (related to options, warrants and preferred stock) that have been excluded from the computations of diluted net loss per common share was 1,169,000 for the year ended December 31, 2011, 1,454,000 for the year ended December 31, 2012 and 2,431,000 for the year ended December 31, 2013.

Stock_Purchase_Warrants

Stock Purchase Warrants	12 Months Ended
	Dec. 31, 2013
Stock Purchase Warrants	'
Stock Purchase Warrants	'
	6.     Stock Purchase Warrants
	The Company has historically issued warrants to purchase shares of the Company’s common stock in connection with certain of its common stock offerings.  The following warrants were outstanding during the years ended December 31, 2011, 2012 and 2013, and include provisions that could require cash settlement of the warrants or have anti-dilution price protection provisions requiring each to be recorded as liabilities of the Company at the estimated fair value at the date of issuance, with changes in estimated fair value recorded as non-cash income or expense in the Company’s statement of operations in each subsequent period:
		January 21, 2010 Class A			December 15, 2010			August 16, 2013
		Warrants			Warrants			Warrants
	Exercise price	$	23.46		$	3.3		$	4.8
	Expiration date	July 21, 2015			December 15, 2015			August 16, 2018
	Total shares issuable on exercise	226,299			15,405			1,133,350
	The 37,007 warrants issued on October 17, 2007 in connection with the Company’s registered direct offering, at an exercise price of $254.40 per share expired unexercised as of April 17, 2013.  The exercise price per share for the January 15, 2010 and December 15, 2010 warrants were adjusted for the anti-dilution provisions triggered by the August 16, 2013 public offering and usage of the Company’s ATM.  The exercise price per share for the August 16, 2013 warrants was adjusted for the anti-dilution provision triggered by the twenty-to-one reverse stock split on October 16, 2013.
	On September 24, 2013, the Company entered into Warrant Exercise Agreements with two holders of the Company’s warrants, which were issued on August 16, 2013.  These agreements allowed the warrant holders to exercise their warrants for 366,650 shares of the Company’s common stock at an exercise price of $7.50 per share, in exchange for 366,650 shares of the Company’s common stock and $1,209,945 of cash.  Proceeds from this arrangement net of $1,209,945 cash paid and issuance costs were approximately $1,470,000.
	All of the warrants listed above could require net cash settlement in the event that registered shares are not available at the time of exercise of such warrant.  The Class A warrants and the December 2010 warrants also contain anti-dilution provisions that adjust the exercise price of the warrant if the Company issues or sells, or is deemed to have issued or sold, any shares of its common stock or securities exercisable or convertible into shares of common stock for no consideration or for a consideration per share less than the applicable exercise price in effect immediately prior to the time of such issue or sale.  In the event of such a subsequent issuance of common stock of the Company, (i) the exercise price of the Class A warrants would be adjusted to a point between the current exercise price per share of such Class A warrant and the price per share at which the new shares of common stock of the Company are being issued based on a weighted average calculation as outlined in the Class A warrant agreement, and (ii) the exercise price of the December 2010 warrants would be adjusted to the price per share at which the new shares of common stock of the Company are being issued.  Notwithstanding the foregoing, there are certain issuances of the Company that would not trigger the anti-dilution provisions of the Class A warrants or the December 2010 warrants, including but not limited to, issuances under any duly authorized Company stock option, restricted stock plan or stock purchase plan whether now existing or hereafter approved by the Company and its stockholders in the future, or as an inducement grant to employees, consultants, directors or officers.  The December 2010 warrants also contain a feature that allows the warrant holder to put the warrants back to the Company and receive cash in the event of a fundamental transaction, such as a change in control of the Company or a sale of all or substantially all of its assets.  The value received by the warrant holder upon exercise of the put right is based on a Black-Scholes model using a defined set of inputs outlined in the December 2010 warrant agreement.
	The Class A warrants and the December 2010 warrants are measured using the Monte Carlo valuation model, while the other warrants listed above are measured using the Black-Scholes valuation model.  Both of the methodologies are based, in part, upon inputs for which there is little or no observable market data, requiring the Company to develop its own assumptions.  The assumptions used in calculating the estimated fair value of the warrants represent the Company’s best estimates; however, these estimates involve inherent uncertainties and the application of management judgment.  As a result, if factors change and different assumptions are used, the warrant liabilities and the change in estimated fair value of the warrants could be materially different.
	Inherent in both the Monte Carlo and Black-Scholes valuation models are assumptions related to expected stock-price volatility, expected life, risk-free interest rate and dividend yield.  The Company estimates the volatility of its common stock based on historical volatility that matches the expected remaining life of the warrants.  The risk-free interest rate is based on the U.S. Treasury zero-coupon yield curve on the grant date for a maturity similar to the expected remaining life of the warrants.  The expected life of the warrants is assumed to be equivalent to their remaining contractual term.  The dividend rate is based on the historical rate, which the Company anticipates to remain at zero.
	The Monte Carlo model is used for the Class A warrants and the December 2010 warrants to appropriately value the potential future exercise price adjustments triggered by the anti-dilution provisions as well as the value of the put feature of the December 2010 warrants.  These both require Level 3 inputs which are based on the Company’s estimates of the probability and timing of potential future financings and fundamental transactions.  The other assumptions used by the Company are summarized in the following tables for warrants that were outstanding as of any of the balance sheet dates presented on our consolidated balance sheets:
	January 2010 Class A Warrants	December 31, 2012			December 31, 2013
	Closing stock price	$	25.2		$	3.23
	Expected dividend rate	0		%	0		%
	Expected stock price volatility	74		%	84.6		%
	Risk-free interest rate	0.4		%	0.3		%
	Expected life (years)	2.5			1.5
	December 2010 Warrants	December 31, 2012			December 31, 2013
	Closing stock price	$	25.2		$	3.23
	Expected dividend rate	0		%	0		%
	Expected stock price volatility	70.1		%	80.4		%
	Risk-free interest rate	0.4		%	0.4		%
	Expected life (years)	2.96			1.96
	August 2013 Warrants	December 31, 2012			December 31, 2013
	Closing stock price	$	—		$	3.23
	Expected dividend rate	—			0		%
	Expected stock price volatility	—			77.5		%
	Risk-free interest rate	—			1.6		%
	Expected life (years)	—			4.63
	The following table summarizes the change in the estimated fair value of the Company’s warrant liabilities (in thousands):
	Warrant Liabilities
	Balance at December 31, 2011	$	16,625
	Warrants exchanged for common stock	(10,382		)
	Decrease in fair value	(4,248		)
	Balance at December 31, 2012	1,995
	Warrant issuance	5,874
	Warrant exercises	(513		)
	Decrease in fair value	(5,337		)
	Balance at December 31, 2013	$	2,019

Income_Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2013
Income Taxes	'
Income Taxes	'
	7.  Income Taxes
	A reconciliation of income taxes computed using the federal statutory rate to the taxes reported in our consolidated statements of operations is as follows (in thousands):
		Year Ended			Year Ended			Year Ended
		December 31,			December 31,			December 31,
		2011			2012			2013
	Loss before income taxes	$	19,668		$	29,474		$	15,622
	Federal statutory rate	34		%	34		%	34		%
	Taxes computed at federal statutory rate	(6,687		)	(10,021		)	(5,311		)
	Warrants	(3,172		)	(1,445		)	(1,815		)
	Nondeductible stock compensation	1,559			872			81
	Michigan business tax repeal	1,214			—			—
	Michigan NOL benefit	—			(1,229		)	(791		)
	Net operating loss expirations	—			612			612
	Other	336			300			(27		)
	Change in valuation allowance	6,750			10,911			7,251
	Reported income taxes	$	—		$	—		$	—
	Deferred tax assets consist of the following (in thousands):
		Year Ended			Year Ended
		December 31,			December 31,
		2012			2013
	Net operating loss carryforwards	$	63,959		$	70,738
	Research and development credit carryforwards	1,600			1,600
	Employee benefits and stock compensation	1,314			1,655
	Other, net	393			524
	Total deferred tax assets	67,266			74,517
	Valuation allowance	(67,266		)	(74,517		)
	Net deferred tax assets	$	—		$	—
	As of December 31, 2013, the Company’s U.S. federal net operating loss, state tax net operating loss and tax credit carryforwards are $202,105,000, $50,133,000 and $1,600,000, respectively.  These net operating loss carryforwards will expire between 2014 and 2033.  The tax credit carryforwards will expire between 2019 and 2027.  Effective January 1, 2012, the Michigan Business Tax (MBT) has been repealed.  As a result of this repeal, the MBT net operating loss of $65,520,000 will not carry forward and has been derecognized in 2011.
	The Company’s net operating losses are subject to the limitations imposed under section 382 of the Internal Revenue Code. These limits are triggered when a change in control occurs, and are computed based upon several variable factors including the share price of the Company’s common stock on the date of the change in control. A change in control is generally defined as a cumulative change of 50% or more in the ownership positions of certain stockholders during a rolling three year period.  Based on common stock issuances over the Company’s history and the likelihood of additional issuances, it is possible that the use of the Company’s existing net operating losses will be limited. If a limitation occurs, it is likely that a significant portion of the net operating losses will expire unutilized regardless of the amount of future profitability.
	Due to the historical losses incurred by the Company, a full valuation allowance for deferred tax assets, including the deferred tax assets for the aforementioned net operating losses and credits, has been provided since they are not more likely than not to be realized.  If the Company achieves profitability, these deferred tax assets may be available to offset future income taxes.  The increase in the valuation allowance was $10,911,000 and $7,251,000 for the years ended December 31, 2012 and 2013, respectively.  Errors were identified in the December 31, 2012 income tax disclosure with respect to the amount recorded for warrants and the state NOL benefit within the effective rate reconciliation that resulted in the net operating loss carryforward and the associated valuation allowance being understated by $2,785,000.  In addition, the amounts of federal and state net operating loss carryforwards were understated by $2,890,000 and overstated by $105,000, respectively.  In accordance with the SEC’s Staff Accounting Bulletin Nos. 99 and 108 (SAB 99 and SAB 108), the Company evaluated the errors and, based on an analysis of quantitative and qualitative factors determined that they were immaterial to the prior reporting periods affected.  As the errors have no impact on any amounts presented in the previously issued balance sheets, statement of operations or statement of cash flows for any prior periods, the Company has determined that it is appropriate to revise the 2012 prior year amounts presented above to reflect the corrected disclosure.
	The Company assesses uncertain tax positions in accordance with the provisions of Financial Accounting Standards Board Accounting Standards Codification (ASC) 740-10-5, “Accounting for Uncertain Tax Positions.”  This pronouncement prescribes a recognition threshold and measurement methodology for recording within the financial statements uncertain tax positions taken, or expected to be taken, in the Company’s income tax returns.  As of December 31, 2012 and 2013, the Company had an unrecognized tax benefit associated with research and development tax credits of $2,100,000 and $900,000, respectively.  The uncertain tax position has been reduced due to the expiration of the statute.  Income tax expense would be reduced by zero if the gross unrecognized tax benefits were recognized due to the valuation allowance.  It is not anticipated that the unrecognized tax benefits will significantly increase or decrease within the next twelve months.
	The Company files U.S. federal Michigan and California income tax returns.  Due to the Company’s net operating loss carryforwards, Federal income tax returns from incorporation are still subject to examination.  Michigan tax returns for the year ended December 31, 2011 and forward are subject to examination. California tax returns for the year ended December 31, 2012 and forward are subject to examination.

Licenses_Royalties_and_Collabo

Licenses, Royalties and Collaborative Agreements and Commitments	12 Months Ended
	Dec. 31, 2013
Licenses, Royalties and Collaborative Agreements and Commitments	'
Licenses, Royalties and Collaborative Agreements and Commitments	'
	8.     Licenses, Royalties and Collaborative Agreements and Commitments
	University of Michigan — In August 1989, the Company entered into a research agreement with the University of Michigan (the University).  In March 1992, and as provided for under the research agreement, the Company also entered into a license agreement for the technology developed under the research agreement.  The license agreement, as amended, provides for a royalty to be paid to the University equal to 2% of net sales of products containing the licensed technology sold by the Company.  Such royalties have been nominal since Inception.  This license agreement will expire in 2014.
	Corning Incorporated — In December 2002, the Company entered into an agreement with Corning Incorporated (Corning) that granted Corning an exclusive sublicense relating to the Company’s cell transfection technology.  Under the terms of the agreement, the Company retains exclusive rights to the applications of the technologies involving cells for therapeutic applications.  In addition, the agreement provides for future royalty payments on net sales of licensed products sold under the sublicense amounting to 5% of such sales up to $50,000,000.  However, the Company does not expect to receive material revenue from this source for several years, if ever.
	RealBio Technologies — In May 2009, the Company entered into an agreement with RealBio Technologies, Inc. (RealBio) that granted RealBio an exclusive license to utilize our technology outside of the Company’s core area of focus - human regenerative medicine. In return for this license, the Company received a minority equity interest in RealBio, which was not material as of December 31, 2013.
	Manufacture, Supply and Other Agreements — The Company has entered into various agreements relating to the manufacture of its products and the supply of certain components.  If the manufacturing or supply agreements expire or are otherwise terminated, the Company may not be able to identify and obtain ancillary materials that are necessary to develop its product and such expiration and termination could have a material effect on the Company’s business.

Commitments_Contingencies_and_

Commitments, Contingencies and Debt	12 Months Ended
	Dec. 31, 2013
Commitments, Contingencies and Debt	'
Commitments, Contingencies and Debt	'
	9.     Commitments, Contingencies and Debt
	During 2013, the Company amended its operating lease with Domino’s Farms Office Park, LLC to extend the term of the lease for an additional five years, which began on May 1, 2013.  The Company now has a right to terminate on the third anniversary of the renewal, and has two five-year market value renewal options.  The Company’s leased facility includes a Class 100,000 modular manufacturing clean room, laboratories and office space.  The lease also provides the Company the right of first refusal on certain additional space.
	As of December 31, 2013, future minimum payments related to our operating and capital leases are as follows (in thousands):
				Payments Due by Period
	Contractual Obligations	Total		2014		2015		2016		2017		2018
	Operating leases	$	3,859	$	889	$	891	$	892	$	893	$	294
	Capital leases	6		6		—		—		—		—
	Total	$	3,865	$	895	$	891	$	892	$	893	$	294
	Rent expense for the years ended December 31, 2011, 2012 and 2013, and for the period from March 24, 1989 (Inception) to December 31, 2013, was $1,099,000, $1,127,000, $986,000 and $14,205,000 respectively.

Employee_Savings_Plan

Employee Savings Plan	12 Months Ended
	Dec. 31, 2013
Employee Savings Plan	'
Employee Savings Plan	'
	10. Employee Savings Plan
	The Company has a 401(k) savings plan that allows participating employees to contribute a portion of their salary, subject to annual limits and minimum qualifications.  The Board may, at its sole discretion, approve Company matching contributions to the plan.  The Company made contributions of $159,000, $202,000 and $144,000 for the years ended December 31, 2011, 2012 and 2013, respectively, and $2,050,000 for the period from March 24, 1989 (Inception) to December 31, 2013.

Preferred_Stock

Preferred Stock	12 Months Ended
	Dec. 31, 2013
Preferred Stock	'
Preferred Stock	'
	11. Preferred Stock
	Shareholder Rights Plan - Series A Junior Participating Cumulative Preferred Stock
	On August 11, 2011, the Board of Directors of the Company adopted a Shareholder Rights Plan, as set forth in the Shareholder Rights Agreement between the Company and the rights agent, the purpose of which is, among other things, to enhance the Board’s ability to protect shareholder interests and to ensure that shareholders receive fair treatment in the event any coercive takeover attempt of the Company is made in the future.  The Shareholder Rights Plan could make it more difficult for a third party to acquire, or could discourage a third party from acquiring, the Company or a large block of the Company’s common stock.  In March 2012, the Board approved an amendment to the Shareholder Rights Plan to enable Eastern Capital Limited and its affiliates to purchase up to 49.9% of the shares of common stock of the Company without becoming an “acquiring person” and thereby triggering the stockholder rights, with the limitations under the Shareholder Rights Plan remaining in effect for all other stockholders of the Company.  The following summary description of the Shareholder Rights Plan should be read in conjunction with the Company’s Shareholder Rights Plan, which was filed with the Securities and Exchange Commission as an exhibit to a Registration Statement on Form 8-A on August 12, 2011, and in conjunction with Amendment No.1 to Shareholder Rights Agreement, which was filed with the Securities and Exchange Commission as an exhibit to a Current Report on Form 8-K on March 9, 2012.
	In connection with the adoption of the Shareholder Rights Plan, the Board of Directors of the Company declared a dividend distribution of one preferred stock purchase right (a “Right”) for each outstanding share of common stock to stockholders of record as of the close of business on August 15, 2011.  In addition, one Right will automatically attach to each share of common stock issued between August 15, 2011 and the distribution date.  As a result of the October 2013 reverse stock split, the number of Rights associated with each share of common stock was automatically proportionately adjusted so that (i) twenty rights were then associated with each outstanding share of common stock and (ii) so long as the Rights are attached to the common stock, twenty rights shall be deemed to be delivered for each share of common stock issued or transferred by the Company in the future.  The Rights currently are not exercisable and are attached to and trade with the outstanding shares of common stock.  Each Right entitles the registered holder of common stock to purchase from the Company a unit consisting of one ten-thousandth of a share (a “Unit”) of Series A Junior Participating Preferred Stock, no par value per share, at a cash exercise prices of $30.00 per Unit.  There are currently 45,000 shares authorized and zero issued and outstanding.  Under the Shareholder Rights Plan, the Rights become exercisable if a person or group becomes an “acquiring person” by acquiring 15% or more of the outstanding shares of common stock or if a person or group commences a tender offer that would result in that person owning 15% or more of the common stock.  If a person or group becomes an “acquiring person,” each holder of a Right (other than the acquiring person and its affiliates, associates and transferees) would be entitled to purchase, at the then-current exercise price, such number of shares of the Company’s preferred stock which are equivalent to shares of common stock having a value of twice the exercise price of the Right.  If the Company is acquired in a merger or other business combination transaction after any such event, each holder of a Right would then be entitled to purchase, at the then-current exercise price, shares of the acquiring company’s common stock having a value of twice the exercise price of the Right.
	The Rights may be redeemed in whole, but not in part, at a price of $0.001 per Right (payable in cash, common stock or other consideration deemed appropriate by the Board of Directors) by the Board of Directors only until the earlier of (i) the time at which any person becomes an “acquiring person” or (ii) the expiration date of the Rights Agreement.  Immediately upon the action of the Board of Directors ordering redemption of the Rights, the Right will terminate and thereafter the only right of the holders of Rights will be to receive the redemption price.  The Rights will expire at the close of business on August 15, 2021, unless previously redeemed or exchanged by the Company as described above.
	Series B Convertible Preferred Stock
	On March 9, 2012, the Company completed the sale of 12,308 shares of Series B-1 Non-Voting Convertible Preferred Stock (Series B-1 preferred stock) at an offering price of $3,250 per share.  In addition to the Series B-1 preferred stock, which was issued at the closing, the Company also authorized Series B-2 Voting Convertible preferred Stock (Series B-2 preferred stock).  The Series B-1 preferred stock and Series B-2 preferred stock collectively are referred to as the Series B preferred stock.  The Series B preferred stock is convertible, at the option of the holder thereof at any time after the five year anniversary of the closing of the offering, into shares of common stock at a conversion price of $3.25 per share of common stock, at a conversion ratio of one share of preferred stock for fifty shares of common stock.  At any time after the five year anniversary of issuance, the Company may elect to convert any or all outstanding shares of Series B preferred stock into shares of common stock, subject to certain limitations.  Dividends on the Series B preferred stock will be cumulative and compound daily, at a rate of 11.5% per annum, payable upon conversion, liquidation, redemption or other similar events, and payable in cash or Series B-1 preferred stock until the five year anniversary of issuance.  As of December 31, 2013, there are 142,700 accumulated but undeclared Series B-1 dividends.  Unless prohibited by Michigan law governing distributions to shareholders, the Series B-1 preferred stock shall be redeemable at the option of holder of the Series B-1 preferred stock commencing at any time after the five year anniversary of issuance, liquidation, winding up, dissolution or other similar events, subject to certain terms and limitations.
	The Series B preferred stock does not, in its entirety, require liability classification and was evaluated for embedded features to determine if those features require bifurcation and separate classification as derivative liabilities.  The Series B preferred stock host contract was evaluated for equity or mezzanine classification based upon the nature of the redemption and conversion features.  Generally, any feature that could require cash redemption for matters not within the Company’s control, irrespective of probability of the event occurring, requires classification outside of shareholders’ equity.  The Series B preferred stock was initially recorded as mezzanine in the Consolidated Balance Sheets and was accreted to its redemption value through charges to Deficit accumulated during the development stage using the effective interest method.
	On August 12, 2013, the Company amended the Series B preferred stock agreement to remove the cash redemption provision, modify the liquidation preferences for the Series B-2 preferred stock and to increase the redemption price for the Series B-1 preferred stock.  The redemption price, prior to the five year anniversary, is now equal to $7,430 multiplied by the number of Series B-1 preferred shares redeemed minus the Company’s closing stock price multiplied by the number of common shares into which the outstanding Series B-2 preferred stock are convertible.  The redemption price, after the five year anniversary, is the amount equal to the greater of the Series B offering price plus accrued dividends or the conversion value in common stock.  As a result of the amendment to the agreement, the total amount of $38,389,000 Series B preferred stock has been reclassified from mezzanine into shareholders’ equity (deficit).
	The total reclassification amount includes a correction of a classification error the Company discovered regarding its previous reporting for the accretion of the Series B-1 preferred stock carrying value.  The error resulted in an overstatement of the carrying value of the Series B-1 preferred stock in mezzanine and a corresponding overstatement of deficit accumulated during the development stage by $4,487,000 as of September 30, 2013.  The total correction as it relates to the previous year is $3,224,000.  In accordance with the SEC’s staff Accounting Bulletin Nos. 99 and 108 (SAB 99 and SAB 108), the Company evaluated this error and, based on an analysis of quantitative and qualitative factors determined that the error was immaterial to the prior reporting periods affected, therefore, the Company corrected the error in the current filing.

Restructuring

Restructuring	12 Months Ended
	Dec. 31, 2013
Restructuring	'
Restructuring	'
	12. Restructuring
	On March 27, 2013, the Company announced a strategic change in its research and development programs to focus on the clinical development of ixmyelocel-T for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy (DCM).  The Company, which recently initiated the Phase 2b ixCELL-DCM clinical trial, previously received a U.S. orphan drug designation for the use of ixmyelocel-T in the treatment of DCM.  As a result of the strategic change, the Company stopped enrollment of the Phase 3 REVIVE clinical trial in patients with critical limb ischemia (CLI).  In addition, the Company executed a corporate restructuring that reduced staff and operating expenses.  Employees directly affected by the restructuring plan were provided with severance payments and outplacement assistance.
	As a result of the ceasing of enrollment in the Phase 3 REVIVE clinical trial, the Company recorded a one-time restructuring charge of $408,000 in the first quarter of 2013.  The restructuring accrual decreased to $21,000 as of December 31, 2013 as a result of cash payments made for severance and other personnel-related expenses.

Subsequent_Event

Subsequent Event	12 Months Ended
	Dec. 31, 2013
Subsequent Event	'
Subsequent Event	'
	13.          Subsequent Event
	On January 21, 2014, the Company entered into a purchase agreement with Lincoln Park Capital Fund, LLC (Lincoln Park) to sell to Lincoln Park up to $15,000,000 in shares of its common stock, subject to certain limitations, from time to time over the 30-month period.  The Company may direct Lincoln Park, at its sole discretion, to purchase up to 50,000 shares of common stock in regular purchases, increasing to amounts of up to 100,000 shares depending upon the closing sale price of the common stock.  In addition, the Company may direct Lincoln Park to purchase additional amounts as accelerated purchases if on the date of a regular purchase the closing sale price of the common stock equals or exceeds $3.00 per share.  The purchase price of shares of common stock related to the future funding will be based on the prevailing market prices of such shares at the time of sales (or over a period of up to 10 business days leading up to such time), but in no event will shares be sold to Lincoln Park on a day the common stock closing price is less than the floor price of $2.50, subject to adjustment.  The Company will control the timing and amount of any sales of common stock to Lincoln Park.

Organization_and_Summary_of_Si1

Organization and Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2013
Organization and Summary of Significant Accounting Policies	'
Reverse Stock Split	'
	Reverse Stock Split — On October 16, 2013, the Company completed a twenty-to-one reverse stock split.  Accordingly, all references to numbers of common stock and per share data in the accompanying financial statements have been adjusted to reflect the reverse stock split on a retroactive basis.
Principles of Consolidation	'
	Principles of Consolidation — The consolidated financial statements include the accounts of Aastrom and its wholly-owned subsidiary, Aastrom Biosciences GmbH, located in Berlin, Germany and Marrow Donation, LLC located in San Diego, California (collectively, the Company).  All inter-company transactions and accounts have been eliminated in consolidation.
Fair Value Measurements	'
	Fair Value Measurements — Fair value is the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants.  As such, fair value is determined based upon assumptions that market participants would use in pricing an asset or liability.  Fair value measurements are rated on a three-tier hierarchy as follows:
	·             Level 1 inputs: Quoted prices (unadjusted) for identical assets or liabilities in active markets;
	·             Level 2 inputs: Inputs, other than quoted prices included in Level 1, that are observable either directly or indirectly; and
	·             Level 3 inputs: Unobservable inputs for which there is little or no market data, which require the reporting entity to develop its own assumptions.
	In many cases, a valuation technique used to measure fair value includes inputs from multiple levels of the fair value hierarchy described above.  The lowest level of significant input determines the placement of the entire fair value measurement in the hierarchy.
	The following table presents the Company’s liabilities that are measured at fair value on a recurring basis at December 31, 2012 and 2013:
		December 31, 2012
		Level 1		Level 2		Level 3
	Warrant liabilities	—		—		$	1,995,000
		December 31, 2013
		Level 1		Level 2			Level 3
	Warrant liabilities	—		$	1,934,000		$	85,000
	A reconciliation of beginning and ending balances for the Company’s fair value measurements using Level 3 inputs is as follows:
	Warrants (in thousands):
		December 31,			December 31,
		2012			2013
	Beginning balance	$	16,625		$	1,995
	Warrants exchanged for common stock	(10,382		)	—
	Warrant issuance	—			5,874
	Warrant exercises	—			(513		)
	Transfers to level 2	—			(2,505		)
	Decrease in fair value	(4,248		)	(4,766		)
	Ending balance	$	1,995		$	85
	The Company utilizes the actual date of an event or change in circumstances to determine if a transfer in or out of a level has occurred.  After the execution of the reverse stock split, the August 2013 warrants no longer contain any anti-dilution provisions that would require Level 3 disclosure.  As a result, they were reclassified to Level 2.  See Note 6 for disclosures related to the fair value of the Company’s warrants.  The Company does not have any other assets or liabilities on the balance sheet as of December 31, 2013 that are measured at fair value.
Diversity of Credit Risk	'
	Diversity of Credit Risk — The Company has established guidelines relative to diversification and maturities of its investments in an effort to limit risk.  These guidelines are periodically reviewed and modified to take advantage of trends in yields and interest rates.
Property and Equipment	'
	Property and Equipment — Property and equipment is recorded at cost and depreciated or amortized using the straight-line method over the estimated useful life of the asset (primarily three to five years) or the underlying lease term for leasehold improvements, whichever is shorter.  When assets are disposed of, the cost and accumulated depreciation are removed from the accounts.  Repairs and maintenance are charged to expense as incurred.
Revenue Recognition	'
	Revenue Recognition — The Company’s revenue can be generated from grants and research agreements, collaborative agreements, licensing fees and product sales.  Revenue from grants and research agreements is recognized on a cost reimbursement basis consistent with the performance requirements of the related agreement.  Revenue from collaborative agreements is recognized when the scientific or clinical results stipulated in the agreement have been met and there are no ongoing obligations on the Company’s part.  Revenue from product sales is recognized when title to the product transfers and there are no remaining obligations that will affect the customer’s final acceptance of the sale.  Revenue from licensing fees under licensing agreements is recognized when there are no future performance obligations remaining with respect to such revenues.  Payments received before all obligations are fulfilled are classified as deferred revenue.
Research and Development Costs	'
	Research and Development Costs — Research and development costs are expensed as incurred.  These costs include direct research and development costs such as salaries, clinical trial expenses, consulting fees and other expenses that are specific to the Company’s research and development programs, as well as an allocation of indirect costs such as facility expenses, human resources and information technology expenses.
Stock-Based Compensation	'
	Stock-Based Compensation — Calculating stock-based compensation expense requires the input of highly subjective assumptions.  We apply the Black-Scholes option-pricing model to determine the fair value of our stock options.  Inherent in this model are assumptions related to expected stock-price volatility, option life, risk-free interest rate and dividend yield.  We estimate the volatility of our common stock at the date of grant based on historical volatility.  We estimate the expected life of options that vest solely on service using the “simplified method” provided for in the Securities and Exchange Commission Staff Accounting Bulletin No. 110.  The “simplified method” is permitted for estimating the expected term of “plain-vanilla” stock options for which the historical stock option exercise experience is likely not indicative of future exercise patterns.  The risk-free interest rate is based on the U.S. Treasury zero-coupon yield curve on the grant date for a maturity similar to the expected life of the options. The dividend rate is based on our historical rate, which we anticipate to remain at zero.  The assumptions used in calculating the fair value of stock options represent our best estimates; however, these estimates involve inherent uncertainties and the application of management judgment.  As a result, if factors change and different assumptions are used, the stock-based compensation expense could be materially different in the future.  In addition, we are required to estimate the expected forfeiture rate and only recognize expense for those stock options expected to vest over the service period.  We estimate the forfeiture rate considering the historical experience of our stock-based awards.  If the actual forfeiture rate is different from the estimate, we adjust the expense accordingly.
Income Taxes	'
	Income Taxes — Deferred tax assets are recognized for deductible temporary differences and tax credit carryforwards and deferred tax liabilities are recognized for taxable temporary differences.  Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized.
Net Loss Per Share Attributable to Common Shareholders'	'
	Net Loss Per Share Attributable to Common Shareholders’— Basic earnings (loss) per share is calculated using the two-class method, which is an earnings allocation formula that determines earnings (loss) per share for the holders of the Company’s common shares and holders of the Series B preferred stock.  The Series B preferred stock shares contain participation rights in undistributed earnings, but do not share in the losses of the Company.  The accumulated but undeclared dividends on the Series B preferred stock of $9,275,000 are treated as a reduction of earnings attributable to common shareholders.
Use of Estimates	'
	Use of Estimates — The preparation of financial statements in accordance with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reported period. Actual results could differ from those estimates.
Financial Instruments	'
	Financial Instruments — The Company’s financial instruments include receivables for which the current carrying amounts approximate market value based upon their short-term nature.
Warrants	'
	Warrants — Warrants that could be cash settled or have anti-dilution price protection provisions are recorded as liabilities at their estimated fair value at the date of issuance, with subsequent changes in estimated fair value recorded in other income (expense) in our statement of operations in each subsequent period.  In general, warrants with anti-dilution provisions are measured using the Monte Carlo valuation model, while the others are measured using the Black-Scholes valuation model.  Both of the methodologies are based, in part, upon inputs for which there is little or no observable market data, requiring the Company to develop its own assumptions.  The assumptions used in calculating the estimated fair value of the warrants represent our best estimates; however, these estimates involve inherent uncertainties and the application of management judgment.  As a result, if factors change and different assumptions are used, the warrant liability and the change in estimated fair value could be materially different.
Long-Lived Assets	'
	Long-Lived Assets — The Company reviews its long-lived assets for impairment whenever an event or change in circumstances indicates that the carrying values of an asset may not be recoverable.  If such an event or change in circumstances occurs and potential impairment is indicated because the carrying values exceed the estimated future undiscounted cash flows of the asset, the Company would measure the impairment loss as the amount by which the carrying value of the asset exceeds its fair value. No significant events or changes in circumstances were identified by the Company that would indicate that the carrying value of an asset was not recoverable for any of the periods presented in the accompanying consolidated financial statements.

Organization_and_Summary_of_Si2

Organization and Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2013
Organization and Summary of Significant Accounting Policies	'
Schedule of Company's liabilities that are measured at fair value on a recurring basis	'
		December 31, 2012
		Level 1		Level 2		Level 3
	Warrant liabilities	—		—		$	1,995,000
		December 31, 2013
		Level 1		Level 2			Level 3
	Warrant liabilities	—		$	1,934,000		$	85,000
Schedule of reconciliation of beginning and ending balances for the Company's fair value measurements using Level 3 inputs	'
	Warrants (in thousands):
		December 31,			December 31,
		2012			2013
	Beginning balance	$	16,625		$	1,995
	Warrants exchanged for common stock	(10,382		)	—
	Warrant issuance	—			5,874
	Warrant exercises	—			(513		)
	Transfers to level 2	—			(2,505		)
	Decrease in fair value	(4,248		)	(4,766		)
	Ending balance	$	1,995		$	85

Selected_Balance_Sheet_Informa1

Selected Balance Sheet Information (Tables)	12 Months Ended
	Dec. 31, 2013
Selected Balance Sheet Information	'
Schedule of property and equipment	'
	Property and Equipment (in thousands):
		December 31,			December 31,
		2012			2013
	Machinery and equipment	$	2,507		$	2,547
	Furniture and fixtures	706			706
	Computer software	193			193
	Computer equipment	307			307
	Office equipment	55			55
	Leasehold improvements	1,018			1018
		4,786			4,826
	Less accumulated depreciation	(3,598		)	(4,087		)
		$	1,188		$	739
Schedule of accounts payable and accrued expenses	'
	Accounts Payable and Accrued Expenses (in thousands):
		December 31,			December 31,
		2012			2013
	Accounts payable	$	2,843		$	2,355
	Accrued expenses	404			321
		$	3,247		$	2,676
Schedule of accrued employee benefits	'
	Accrued Employee Benefits (in thousands):
		December 31,			December 31,
		2012			2013
	Vacation pay and other	$	383		$	233
	Bonus	—			387
		$	383		$	620

StockBased_Compensation_Tables

Stock-Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2013
Stock-Based Compensation	'
Schedule of weighted average assumptions used to estimate fair value of each service-based stock option grant	'
		Year Ended		Year Ended		Year Ended
		December 31,		December 31,		December 31
	Service-Based Stock Options	2011		2012		2013
	Expected dividend rate	0%		0%		0%
	Expected stock price volatility	72.1% – 78.9%		73.9% – 79.1%		74.0% – 87.9%
	Risk-free interest rate	1.4% – 2.7%		0.9% – 1.5%		0.1% – 2.1%
	Expected life (years)	6.0 – 6.3		5.5 – 6.3		5.0 – 6.3
Summary of activity for service-based stock options	'
	Service-Based Stock Options	Options		Weighted Average			Weighted Average	Aggregate
				Exercise Price			Remaining	Intrinsic
							Contractual Term	Value
	Outstanding at December 31, 2010	214,860		$	48.6		8.9	$	3,159,000
	Granted	215,528		$	46.2
	Exercised	(984	)	$	32.8			$	21,000
	Forfeited or expired	(25,420	)	$	46.6
	Outstanding at December 31, 2011	403,984		$	47.6		8.4	$	674,000
	Granted	273,372		$	44.2
	Exercised	(7,208	)	$	29.6			$	52,000
	Cancelled	(52,885	)	$	40.6
	Forfeited or expired	(117,889	)	$	43.6
	Outstanding at December 31, 2012	499,374		$	47.6		7.5	$	—
	Granted	75,751		$	21.32
	Exercised	—		$	—			$	—
	Expired	(164,189	)	$	51.76
	Forfeited	(113,076	)	$	45.38
	Outstanding at December 31, 2013	297,860		$	39.53		7.9	$	—
	Exercisable at December 31, 2013	146,003		$	45.37		7.2	$	—

Net_Loss_Per_Common_Share_Tabl

Net Loss Per Common Share (Tables)	12 Months Ended
	Dec. 31, 2013
Net Loss Per Common Share	'
Schedule of net loss attributable to common shareholders and share data used in the basic and diluted earnings per share computations using the two class method	'
		Year Ended			Year Ended			Year Ended
		December 31,			December 31,			December 31,
	(Amounts in thousands, except per share amounts)	2011			2012			2013
	Numerator:
	Net loss	$	(19,668	)	$	(29,474	)	$	(15,622	)
	Less: earnings attributable to convertible preferred stock	—			3,993			5,352
	Numerator of basic and diluted EPS	$	(19,668	)	$	(33,467	)	$	(20,974	)
	Denominator:
	Denominator for basic and diluted EPS: weighted-average common shares outstanding	1,931			2,060			3,016
	Net loss per share attributable to common shareholders (basic and diluted)	$	(10.18	)	$	(16.25	)	$	(6.95	)

Stock_Purchase_Warrants_Tables

Stock Purchase Warrants (Tables)	12 Months Ended
	Dec. 31, 2013
Stock Purchase Warrants	'
Schedule of warrants outstanding	'
		January 21, 2010 Class A			December 15, 2010			August 16, 2013
		Warrants			Warrants			Warrants
	Exercise price	$	23.46		$	3.3		$	4.8
	Expiration date	July 21, 2015			December 15, 2015			August 16, 2018
	Total shares issuable on exercise	226,299			15,405			1,133,350
Schedule of assumptions used in calculating estimated fair value of warrants	'
	January 2010 Class A Warrants	December 31, 2012			December 31, 2013
	Closing stock price	$	25.2		$	3.23
	Expected dividend rate	0		%	0		%
	Expected stock price volatility	74		%	84.6		%
	Risk-free interest rate	0.4		%	0.3		%
	Expected life (years)	2.5			1.5
	December 2010 Warrants	December 31, 2012			December 31, 2013
	Closing stock price	$	25.2		$	3.23
	Expected dividend rate	0		%	0		%
	Expected stock price volatility	70.1		%	80.4		%
	Risk-free interest rate	0.4		%	0.4		%
	Expected life (years)	2.96			1.96
	August 2013 Warrants	December 31, 2012			December 31, 2013
	Closing stock price	$	—		$	3.23
	Expected dividend rate	—			0		%
	Expected stock price volatility	—			77.5		%
	Risk-free interest rate	—			1.6		%
	Expected life (years)	—			4.63
Summary of change in estimated fair value of warrant liabilities	'
	The following table summarizes the change in the estimated fair value of the Company’s warrant liabilities (in thousands):
	Warrant Liabilities
	Balance at December 31, 2011	$	16,625
	Warrants exchanged for common stock	(10,382		)
	Decrease in fair value	(4,248		)
	Balance at December 31, 2012	1,995
	Warrant issuance	5,874
	Warrant exercises	(513		)
	Decrease in fair value	(5,337		)
	Balance at December 31, 2013	$	2,019

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2013
Income Taxes	'
Schedule of reconciliation of income taxes computed using the federal statutory rate to the taxes reported in consolidated statements of operations	'
	A reconciliation of income taxes computed using the federal statutory rate to the taxes reported in our consolidated statements of operations is as follows (in thousands):
		Year Ended			Year Ended			Year Ended
		December 31,			December 31,			December 31,
		2011			2012			2013
	Loss before income taxes	$	19,668		$	29,474		$	15,622
	Federal statutory rate	34		%	34		%	34		%
	Taxes computed at federal statutory rate	(6,687		)	(10,021		)	(5,311		)
	Warrants	(3,172		)	(1,445		)	(1,815		)
	Nondeductible stock compensation	1,559			872			81
	Michigan business tax repeal	1,214			—			—
	Michigan NOL benefit	—			(1,229		)	(791		)
	Net operating loss expirations	—			612			612
	Other	336			300			(27		)
	Change in valuation allowance	6,750			10,911			7,251
	Reported income taxes	$	—		$	—		$	—
Schedule of deferred tax assets	'
	Deferred tax assets consist of the following (in thousands):
		Year Ended			Year Ended
		December 31,			December 31,
		2012			2013
	Net operating loss carryforwards	$	63,959		$	70,738
	Research and development credit carryforwards	1,600			1,600
	Employee benefits and stock compensation	1,314			1,655
	Other, net	393			524
	Total deferred tax assets	67,266			74,517
	Valuation allowance	(67,266		)	(74,517		)
	Net deferred tax assets	$	—		$	—

Commitments_Contingencies_and_1

Commitments, Contingencies and Debt (Tables)	12 Months Ended
	Dec. 31, 2013
Commitments, Contingencies and Debt	'
Schedule of future minimum payments related to operating and capital leases	'
	As of December 31, 2013, future minimum payments related to our operating and capital leases are as follows (in thousands):
				Payments Due by Period
	Contractual Obligations	Total		2014		2015		2016		2017		2018
	Operating leases	$	3,859	$	889	$	891	$	892	$	893	$	294
	Capital leases	6		6		—		—		—		—
	Total	$	3,865	$	895	$	891	$	892	$	893	$	294

Organization_and_Summary_of_Si3

Organization and Summary of Significant Accounting Policies (Details) (USD $)	0 Months Ended	12 Months Ended
	Oct. 16, 2013	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
		item
Organization and Summary of Significant Accounting Policies	'	'	'	'	'
Number of reportable segments	'	1	'	'	'
Cash	'	$8,059,000	$13,638,000	$5,530,000	$31,248,000
Reverse Stock Split	'	'	'	'	'
Reverse stock split ratio	0.05	'	'	'	'
Maximum period before cash and cash equivalents are not sufficient to sustain operations	'	'1 year	'	'	'
Minimum period of uncertainty regarding the entity's ability to maintain liquidity sufficient to operate business effectively	'	'12 months	'	'	'
Liabilities that are measured at fair value on a recurring basis	'	'	'	'	'
Warrant liabilities	'	2,019,000	1,995,000	16,625,000	'
Recurring | Level 2	'	'	'	'	'
Liabilities that are measured at fair value on a recurring basis	'	'	'	'	'
Warrant liabilities	'	1,934,000	'	'	'
Recurring | Level 3	'	'	'	'	'
Liabilities that are measured at fair value on a recurring basis	'	'	'	'	'
Warrant liabilities	'	$85,000	$1,995,000	'	'

Organization_and_Summary_of_Si4

Organization and Summary of Significant Accounting Policies (Details 2) (USD $)	12 Months Ended	297 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2012
			Warrants	Warrants
Reconciliation of beginning and ending balances for the company's fair value measurements using Level 3 inputs	'	'	'	'
Beginning balance	'	'	$1,995	$16,625
Warrants exchanged for common stock	-10,382	-10,382	'	-10,382
Warrant issuance	'	'	5,874	'
Warrant exercises	'	'	-513	'
Transfers to level 2	'	'	-2,505	'
Decrease in fair value	'	'	-4,766	-4,248
Ending balance	'	'	$85	$1,995

Organization_and_Summary_of_Si5

Organization and Summary of Significant Accounting Policies (Details 3)	12 Months Ended
	Dec. 31, 2013
Stock-Based Compensation	'
Anticipated dividend rate (as a percent)	0.00%
Minimum	'
Property and Equipment	'
Estimated useful life	'3 years
Maximum	'
Property and Equipment	'
Estimated useful life	'5 years

Organization_and_Summary_of_Si6

Organization and Summary of Significant Accounting Policies (Details 4) (Series B preferred stock, USD $)	Dec. 31, 2013
Series B preferred stock	'
Net Loss Per Share Attributable to Common Shareholders	'
Accumulated but undeclared dividends	$9,275,000

Selected_Balance_Sheet_Informa2

Selected Balance Sheet Information (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Property and Equipment	'	'
Property and equipment, gross	$4,826	$4,786
Less accumulated depreciation	-4,087	-3,598
Property and equipment, net	739	1,188
Accounts Payable and Accrued Expenses	'	'
Accounts payable	2,355	2,843
Accrued expenses	321	404
Accounts payable and accrued expenses	2,676	3,247
Accrued Employee Benefits	'	'
Vacation pay and other	233	383
Bonus	387	'
Accrued employee benefits	620	383
Machinery and equipment	'	'
Property and Equipment	'	'
Property and equipment, gross	2,547	2,507
Furniture and fixtures	'	'
Property and Equipment	'	'
Property and equipment, gross	706	706
Computer software	'	'
Property and Equipment	'	'
Property and equipment, gross	193	193
Computer equipment	'	'
Property and Equipment	'	'
Property and equipment, gross	307	307
Office equipment	'	'
Property and Equipment	'	'
Property and equipment, gross	55	55
Leasehold improvements	'	'
Property and Equipment	'	'
Property and equipment, gross	$1,018	$1,018

StockBased_Compensation_Detail

Stock-Based Compensation (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Weighted average assumptions used to estimate fair value of each service-based stock option grant	'	'	'	'
Expected dividend rate (as a percent)	0.00%	'	'	'
2009 Plan	'	'	'	'
Stock-Based Compensation	'	'	'	'
Awards available for future grant under the Plan (in shares)	369,342	'	'	'
2004, 2001 and 1992 PLANS	'	'	'	'
Stock-Based Compensation	'	'	'	'
Awards available for future grant under the Plan (in shares)	0	'	'	'
Service-based stock options	'	'	'	'
Stock-Based Compensation	'	'	'	'
Weighted average grant-date fair value (in dollars per share)	$14.07	$24	$30.80	'
Net compensation expense related to employees, consultants and directors (in dollars)	$926,000	$3,610,000	$3,743,000	'
Weighted average assumptions used to estimate fair value of each service-based stock option grant	'	'	'	'
Expected dividend rate (as a percent)	0.00%	0.00%	0.00%	'
Options	'	'	'	'
Outstanding at the beginning of the period (in shares)	499,374	403,984	214,860	'
Granted (in shares)	75,751	273,372	215,528	'
Exercised (in shares)	'	-7,208	-984	'
Expired (in shares)	-164,189	'	'	'
Cancelled (in shares)	'	-52,885	'	'
Forfeited or expired (in shares)	'	-117,889	-25,420	'
Forfeited (in shares)	-113,076	'	'	'
Outstanding at the end of the period (in shares)	297,860	499,374	403,984	214,860
Exercisable at the end of the period (in shares)	146,003	'	'	'
Weighted Average Exercise Price	'	'	'	'
Outstanding at the beginning of the period (in dollars per share)	$47.60	$47.60	$48.60	'
Granted (in dollars per share)	$21.32	$44.20	$46.20	'
Exercised (in dollars per share)	'	$29.60	$32.80	'
Expired (in dollars per share)	$51.76	'	'	'
Cancelled (in dollars per share)	'	$40.60	'	'
Forfeited or expired (in dollars per share)	'	$43.60	$46.60	'
Forfeited (in dollars per share)	$45.38	'	'	'
Outstanding at the end of the period (in dollars per share)	$39.53	$47.60	$47.60	$48.60
Exercisable at the end of the period (in dollars per share)	$45.37	'	'	'
Weighted Average Remaining Contractual Term	'	'	'	'
Outstanding at the beginning of the period	'7 years 10 months 24 days	'7 years 6 months	'8 years 4 months 24 days	'8 years 10 months 24 days
Outstanding at the end of the period	'7 years 10 months 24 days	'7 years 6 months	'8 years 4 months 24 days	'8 years 10 months 24 days
Exercisable at the end of the period	'7 years 2 months 12 days	'	'	'
Aggregate Intrinsic Value	'	'	'	'
Outstanding at the beginning of the period	'	674,000	3,159,000	'
Exercised	'	52,000	21,000	'
Outstanding at the end of the period	'	'	674,000	3,159,000
Additional disclosures	'	'	'	'
Total unrecognized compensation cost (in dollars)	1,621,000	'	'	'
Weighted average period over which unrecognized compensation is expected to be recognized	'2 years 8 months 12 days	'	'	'
Total fair value of options vested (in dollars)	$2,280,000	$2,987,000	$2,182,000	'
Service-based stock options | Minimum	'	'	'	'
Weighted average assumptions used to estimate fair value of each service-based stock option grant	'	'	'	'
Expected stock price volatility (as a percent)	74.00%	73.90%	72.10%	'
Risk-free interest rate (as a percent)	0.10%	0.90%	1.40%	'
Expected life	'5 years	'5 years 6 months	'6 years	'
Service-based stock options | Maximum	'	'	'	'
Weighted average assumptions used to estimate fair value of each service-based stock option grant	'	'	'	'
Expected stock price volatility (as a percent)	87.90%	79.10%	78.90%	'
Risk-free interest rate (as a percent)	2.10%	1.50%	2.70%	'
Expected life	'6 years 3 months 18 days	'6 years 3 months 18 days	'6 years 3 months 18 days	'
Service-based stock options | Non-employee	'	'	'	'
Stock-Based Compensation	'	'	'	'
Vesting period	'1 year	'	'	'
Options	'	'	'	'
Granted (in shares)	15,750	'	'	'
Service-based stock options | 2009 Plan	'	'	'	'
Stock-Based Compensation	'	'	'	'
Expiration period	'10 years	'	'	'
Vesting period	'4 years	'	'	'

Shareholders_Equity_Details

Shareholders' Equity (Details) (USD $)	0 Months Ended	12 Months Ended			297 Months Ended	0 Months Ended	12 Months Ended	0 Months Ended
	Aug. 16, 2013	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2013	Jun. 16, 2011	Dec. 31, 2013	Mar. 06, 2014	Jun. 16, 2011
						MLV	MLV	MLV	MLV
								Subsequent event	Maximum
Shareholders' Equity	'	'	'	'	'	'	'	'	'
Expected proceeds from sale of common stock	'	'	'	'	'	'	'	'	$20,300,000
Percentage of gross proceeds payable as commission	'	'	'	'	'	3.00%	'	'	'
Proceeds from sale of common stock	8,169,000	14,438,000	346,000	32,000	199,492,000	'	4,947,000	5,403,000	'
Total gross proceeds	'	'	'	'	'	'	$5,226,000	'	'

Shareholders_Equity_Details_2

Shareholders' Equity (Details 2) (USD $)	0 Months Ended	12 Months Ended			297 Months Ended	0 Months Ended	12 Months Ended		261 Months Ended	0 Months Ended
	Aug. 16, 2013	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2013	Aug. 16, 2013	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2010	Aug. 16, 2013
						Common Stock	Common Stock	Common Stock	Common Stock	Warrants
Shareholders' Equity	'	'	'	'	'	'	'	'	'	'
Shares of common stock sold	'	'	'	'	'	1,500,000	2,153,000	250,000	1,685,000	'
Warrants sold (in shares)	'	'	'	'	'	'	'	'	'	1,500,000
Common stock issued to the underwriter pursuant to the exercise of its over-allotment option (in shares)	'	'	'	'	'	50,000	'	'	'	'
Warrants issued to the underwriter pursuant to the exercise of its over-allotment option	'	'	'	'	'	'	'	'	'	50,000
Public offering price (in dollars per share)	'	'	'	'	'	$6	'	'	'	'
Net proceeds from issuance of common stock and warrants	$8,169,000	$14,438,000	$346,000	$32,000	$199,492,000	'	'	'	'	'
Fair market value of the warrants	'	5,874,000	'	'	'	'	'	'	'	5,874,000
Public offering price (in dollars per share)	'	'	'	'	'	'	'	'	'	$6
Cash dividends declared and paid	'	'	'	'	$0	'	'	'	'	'

Net_Loss_Per_Common_Share_Deta

Net Loss Per Common Share (Details) (USD $)	12 Months Ended			261 Months Ended	297 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2013
Numerator:	'	'	'	'	'
Net loss	($15,622)	($29,474)	($19,668)	'	($285,976)
Less: earnings attributable to convertible preferred stock	5,352	3,993	'	'	'
NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS	-15,622	-33,467	-19,668	-221,212	'
NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS	($20,974)	'	'	'	'
Denominator:	'	'	'	'	'
Denominator for basic and diluted EPS: weighted-average common shares outstanding	3,016,000	2,060,000	1,931,000	'	'
Net loss per share attributable to common shareholders (basic and diluted) (in dollars per share)	($6.95)	($16.25)	($10.18)	'	'
Aggregate number of common equivalent shares (related to options, warrants and preferred stock) that have been excluded from computations of diluted net loss per common share	2,431,000	1,454,000	1,169,000	'	'

Stock_Purchase_Warrants_Detail

Stock Purchase Warrants (Details) (USD $)

0 Months Ended

12 Months Ended

297 Months Ended

12 Months Ended

0 Months Ended

12 Months Ended

Oct. 16, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Sep. 24, 2013

Dec. 31, 2013

Apr. 17, 2013

Oct. 17, 2007

January 2010 Class A Warrants

January 2010 Class A Warrants

December 2010 Warrants

December 2010 Warrants

August 2013 warrants

August 2013 warrants

October 2007 Warrants

October 2007 Warrants

item

Stock Purchase Warrants

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of warrants issued

'

'

'

'

'

'

'

'

'

'

'

'

37,007

Exercise price per share (in dollars per share)

'

'

'

'

'

$23.46

'

$3.30

'

$7.50

$4.80

$254.40

'

Total shares issuable on exercise

'

'

'

'

'

226,299

'

15,405

'

366,650

1,133,350

'

'

Reverse stock split ratio

0.05

'

'

'

'

'

'

'

'

'

'

'

'

Number of warrant holders

'

'

'

'

'

'

'

'

'

2

'

'

'

Cash paid for warrant exercise

'

'

'

'

'

'

'

'

'

$1,209,945

'

'

'

Net proceeds from exercise of warrants

'

'

'

'

'

'

'

'

'

1,470,000

'

'

'

Consideration to be received on issuance of convertible securities or shares depending upon which warrants contain anti-dilution provisions

'

0

'

'

'

'

'

'

'

'

'

'

'

Assumptions used in calculating the estimated fair value of the warrants

'

'

'

'

'

'

'

'

'

'

'

'

'

Closing stock price (in dollars per share)

'

'

'

'

'

$3.23

$25.20

$3.23

$25.20

'

$3.23

'

'

Expected dividend rate (as a percent)

'

'

'

'

'

0.00%

0.00%

0.00%

0.00%

'

0.00%

'

'

Expected stock price volatility (as a percent)

'

'

'

'

'

84.60%

74.00%

80.40%

70.10%

'

77.50%

'

'

Risk-free interest rate (as a percent)

'

'

'

'

'

0.30%

0.40%

0.40%

0.40%

'

1.60%

'

'

Expected life

'

'

'

'

'

'1 year 6 months

'2 years 6 months

'1 year 11 months 16 days

'2 years 11 months 16 days

'

'4 years 7 months 17 days

'

'

Change in the estimated fair value of warrant liabilities

'

'

'

'

'

'

'

'

'

'

'

'

'

Balance at the beginning of the period

'

1,995,000

16,625,000

'

'

'

'

'

'

'

'

'

'

Warrants exchanged for common stock

'

'

10,382,000

'

10,382,000

'

'

'

'

'

'

'

'

Warrant issuance

'

5,874,000

'

'

'

'

'

'

'

'

'

'

'

Warrant exercises

'

-513,000

'

'

'

'

'

'

'

'

'

'

'

Decrease in fair value

'

-5,337,000

-4,248,000

-9,329,000

-21,874,000

'

'

'

'

'

'

'

'

Balance at the end of the period

'

$2,019,000

$1,995,000

$16,625,000

$2,019,000

'

'

'

'

'

'

'

'

Income_Taxes_Details

Income Taxes (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Reconciliation of income taxes computed using the federal statutory rate to the taxes reported in consolidated statements of operations	'	'	'
Loss before income taxes	$15,622	$29,474	$19,668
Federal statutory rate (as a percent)	34.00%	34.00%	34.00%
Taxes computed at federal statutory rate	-5,311	-10,021	-6,687
Warrants	-1,815	-1,445	-3,172
Nondeductible stock compensation	81	872	1,559
Michigan business tax repeal	'	'	1,214
Michigan NOL benefit	-791	-1,229	'
Net operating loss expirations	612	612	'
Other	-27	300	336
Change in valuation allowance	7,251	10,911	6,750
Deferred tax assets	'	'	'
Net operating loss carryforwards	70,738	63,959	'
Research and development credit carryforwards	1,600	1,600	'
Employee benefits and stock compensation	1,655	1,314	'
Other, net	524	393	'
Total deferred tax assets	74,517	67,266	'
Valuation allowance	($74,517)	($67,266)	'

Income_Taxes_Details_2

Income Taxes (Details 2) (USD $)	12 Months Ended
	Dec. 31, 2013
Net operating loss and tax credit carryforwards	'
Tax credit carryforwards	$1,600,000
MBT net operating loss has been derecognized as a result of repeal	65,520,000
Federal	'
Net operating loss and tax credit carryforwards	'
Net operating loss carryforwards	202,105,000
State	'
Net operating loss and tax credit carryforwards	'
Net operating loss carryforwards	$50,133,000

Income_Taxes_Details_3

Income Taxes (Details 3) (USD $)	12 Months Ended		12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2012
			Error in income tax disclosure
Correction of error	'	'	'
Amount of valuation allowance associated with operating loss carryforward understated	'	'	$2,785,000
Amount of net operating loss carryforward understated	'	'	2,890,000
Amount of net operating loss carryforward overstated	'	'	105,000
Uncertain tax positions	'	'	'
Unrecognized tax benefit associated with research and development tax credits	900,000	2,100,000	'
Minimum cumulative percentage change of ownership over which change in control is considered	50.00%	'	'
Rolling period over which cumulative change of ownership is required for change in control	'3 years	'	'
Reduction in income tax expense if gross unrecognized tax benefits have been recognized due to valuation allowance	$0	'	'

Licenses_Royalties_and_Collabo1

Licenses, Royalties and Collaborative Agreements and Commitments (Details) (USD $)	1 Months Ended
	Mar. 31, 1992	Dec. 31, 2002	Dec. 31, 2002
	University Of Michigan	Corning	Corning
			Maximum
Licenses, Royalties and Collaborative Agreements and Commitments	'	'	'
Royalty revenue as a percentage of net sales of products	2.00%	5.00%	'
Future royalty revenue	'	'	$50,000,000

Commitments_Contingencies_and_2

Commitments, Contingencies and Debt (Details) (USD $)	12 Months Ended			297 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2013
	item
Commitments, Contingencies and Debt	'	'	'	'
Lease term	'5 years	'	'	'
Number of five-year market value renewals	2	'	'	'
Period of market value renewals	'5 years	'	'	'
Rating class of modular manufacturing clean room, laboratories and office space leased	100,000	'	'	'
Operating leases	'	'	'	'
Total	$3,859,000	'	'	$3,859,000
2014	889,000	'	'	889,000
2015	891,000	'	'	891,000
2016	892,000	'	'	892,000
2017	893,000	'	'	893,000
2018	294,000	'	'	294,000
Capital leases	'	'	'	'
Total	6,000	'	'	6,000
2014	6,000	'	'	6,000
Contractual Obligations	'	'	'	'
Total	3,865,000	'	'	3,865,000
2014	895,000	'	'	895,000
2015	891,000	'	'	891,000
2016	892,000	'	'	892,000
2017	893,000	'	'	893,000
2018	294,000	'	'	294,000
Rent expense	$986,000	$1,127,000	$1,099,000	$14,205,000

Employee_Savings_Plan_Details

Employee Savings Plan (Details) (USD $)	12 Months Ended			297 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2013
Employee Savings Plan	'	'	'	'
Contributions made under 401(k) savings plan	$144,000	$202,000	$159,000	$2,050,000

Preferred_Stock_Details

Preferred Stock (Details) (USD $)	0 Months Ended	1 Months Ended		12 Months Ended
	Aug. 15, 2011	Oct. 31, 2013	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2013
	rights	rights	Eastern Capital Limited and its affiliates	Series A Junior Participating Cumulative Preferred Stock	Series A Junior Participating Cumulative Preferred Stock
			Maximum		Minimum
Shareholder Rights Plan	'	'	'	'	'
Percentage of common stock approved to be purchased	'	'	49.90%	'	'
Number of rights for each outstanding share of common stock	1	20	'	'	'
Additional number of rights per common share	1	'	'	'	'
Number of rights deemed to be delivered for each share of common stock issued or transferred	'	20	'	'	'
Number of preferred share purchase rights for each outstanding share of the entity's common stock	'	'	'	0.0001	'
Par value per share (in dollars per share)	'	'	'	$0	'
Cash exercise prices (in dollars per unit)	'	'	'	$30	'
Preferred stock, shares authorized	'	'	'	45,000	'
Preferred stock, shares issued	'	'	'	0	'
Preferred stock, shares outstanding	'	'	'	0	'
Percentage of common stock to be acquired for rights to be exercisable by an individual or group	'	'	'	'	15.00%
Percentage of common stock to be owned for rights to be exercisable by an individual or group commencing a tender offer	'	'	'	'	15.00%
Multiple of the value of common stock acquired (after conversion from preferred) to the exercise price of stock purchase right in the event of an acquiring person event	'	'	'	2	'
Multiple of the value of common stock acquired to the exercise price of stock purchase right in the event of a merger of the entity	'	'	'	2	'
Redemption price per right (in dollars per right)	'	'	'	$0.00	'

Preferred_Stock_Details_2

Preferred Stock (Details 2) (USD $)	12 Months Ended	0 Months Ended	1 Months Ended			12 Months Ended
	Dec. 31, 2013	Mar. 09, 2012	Mar. 31, 2012	Dec. 31, 2013	Aug. 12, 2013	Dec. 31, 2013
	Series B preferred stock	Series B-1 preferred stock	Series B-1 preferred stock	Series B-1 preferred stock	Series B-1 preferred stock	Series B-2 Preferred Stock
Series B Convertible Preferred Stock	'	'	'	'	'	'
Number of shares sold	'	12,308	'	'	'	'
Offering price per share (in dollars per share)	'	$3,250	'	'	'	'
Period of closing of offering after which shares are convertible	'5 years	'	'5 years	'	'	'
Conversion price per share (in dollars per share)	$3.25	'	'	'	'	'
Conversion ratio, the number of shares of common stock received per share of convertible preferred stock	50	'	'	'	'	'
Percentage of cumulative dividend rate	11.50%	'	'	'	'	'
Accumulated but undeclared dividends	$9,275,000	'	'	$142,700	'	'
Redemption price (in dollars per share)	'	'	'	'	$7,430	'
Period for accrual of dividend	'5 years	'	'	'	'	'
Reclassification of Series B preferred stock	'	'	'	'	'	$38,389,000

Preferred_Stock_Details_3

Preferred Stock (Details 3) (Classification error for Series B-1 preferred stock carrying value, USD $)	0 Months Ended	12 Months Ended
	Sep. 30, 2013	Dec. 31, 2012
Classification error for Series B-1 preferred stock carrying value	'	'
Correction of error	'	'
Amount of errors corrected	$4,487,000	$3,224,000

Restructuring_Details

Restructuring (Details) (USD $)	12 Months Ended
	Dec. 31, 2013
Restructuring	'
Restructuring charge	$408,000
Restructuring reserve related to severance payments	$21,000

Subsequent_Event_Details

Subsequent Event (Details) (Subsequent event, Lincoln Park, USD $)	0 Months Ended
	Jan. 21, 2014
Subsequent event	'
Period over which shares of common stock to be purchased	'30 months
Floor price for sale of shares of common stock (in dollars per share)	$2.50
Maximum	'
Subsequent event	'
Value of shares of common stock to be sold	$15,000,000
Number of shares of common stock to be purchased in regular purchases	50,000
Number of shares of common stock to be purchased depending upon the closing sale price of the common stock	100,000
Period of business days over which purchase price of shares of common stock will be determined	'10 days
Minimum	'
Subsequent event	'
Threshold closing sale price of the common stock on the date of a regular purchase to trigger purchase of additional amounts as accelerated purchases (in dollars per share)	$3